195 related articles for article (PubMed ID: 25060252)
1. Myeloproliferative disorders.
Meier B; Burton JH
Emerg Med Clin North Am; 2014 Aug; 32(3):597-612. PubMed ID: 25060252
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative Disorders.
Meier B; Burton JH
Hematol Oncol Clin North Am; 2017 Dec; 31(6):1029-1044. PubMed ID: 29078922
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
4. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative disorders and the hyperviscosity syndrome.
Adams BD; Baker R; Lopez JA; Spencer S
Emerg Med Clin North Am; 2009 Aug; 27(3):459-76. PubMed ID: 19646648
[TBL] [Abstract][Full Text] [Related]
6. Pathology consultation on myeloproliferative neoplasms.
Schmidt AE; Oh ST;
Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
[TBL] [Abstract][Full Text] [Related]
7. Advances in understanding and management of myeloproliferative neoplasms.
Vannucchi AM; Guglielmelli P; Tefferi A
CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
[TBL] [Abstract][Full Text] [Related]
8. Selected parameters of hemostasis in patients with myeloproliferative neoplasms.
Gadomska G; Rość D; Stankowska K; Boinska J; Ruszkowska-Ciastek B; Wieczór R
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):464-70. PubMed ID: 24509338
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloproliferative diseases.
de Lacerda JF; Oliveira SN; Ferro JM
Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
11. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.
Tefferi A; Barbui T
Mayo Clin Proc; 2005 Sep; 80(9):1220-32. PubMed ID: 16178503
[TBL] [Abstract][Full Text] [Related]
12. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Mesa RA; Jamieson C; Bhatia R; Deininger MW; Fletcher CD; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; McMahon B; Mohan SR; Oh S; Padron E; Papadantonakis N; Pancari P; Podoltsev N; Rampal R; Ranheim E; Reddy V; Rein LAM; Scott B; Snyder DS; Stein BL; Talpaz M; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2017 Oct; 15(10):1193-1207. PubMed ID: 28982745
[TBL] [Abstract][Full Text] [Related]
13. The chronic myeloproliferative disorders: an historical perspective.
Steensma DP
Curr Hematol Rep; 2003 May; 2(3):221-30. PubMed ID: 12901343
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative neoplasms: Morphology and clinical practice.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Am J Hematol; 2016 Jun; 91(4):430-3. PubMed ID: 26718907
[TBL] [Abstract][Full Text] [Related]
15. [Myeloproliferative diseases].
Adam Z; Vorlícek J; Matýsková M
Vnitr Lek; 1996 Oct; 42(10):710-6. PubMed ID: 8975464
[TBL] [Abstract][Full Text] [Related]
16. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
17. Practical management of classical myeloproliferative disorder patients: a clinician's guide.
Mesa RA
Future Oncol; 2006 Aug; 2(4):515-24. PubMed ID: 16922618
[TBL] [Abstract][Full Text] [Related]
18. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
Ohyashiki JH
Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
[TBL] [Abstract][Full Text] [Related]
20. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
